Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Poonam Puri

Interventional Cardiology Chattanooga, TN Medical Doctor

NPI 1659577492 CMS profile 30167

979 East Third Street, Suite C-520, Chattanooga, TN 37403

Open in the dashboard

General payments

$14,092

439 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Poonam Puri of Chattanooga, TN is reported in the CMS Open Payments database as having received $14,092 across 439 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,492 68
2024 General $1,566 56
2023 General $1,991 41
2022 General $2,142 64
2021 General $818 37
2020 General $1,552 75
2019 General $2,531 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Poonam Puri
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Poonam Puri were reported at $3,492. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Poonam Puri Interventional Cardiology median Middle half National median
2019 $2,531 $1,097 $329–$3,048 $163
2020 $1,552 $473 $161–$1,480 $114
2021 $818 $677 $233–$1,827 $132
2022 $2,142 $978 $333–$2,724 $149
2023 $1,991 $1,136 $382–$2,986 $160
2024 $1,566 $1,181 $395–$3,326 $164
2025 $3,492 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $2,915 9 payments
  2. Abiomed $1,604 17 payments
  3. Novartis Pharmaceuticals Corporation $1,532 94 payments
  4. Medtronic, Inc. $866 27 payments
  5. Shockwave Medical, Inc $861 15 payments
  6. Boston Scientific Corporation $831 23 payments
  7. Abbott Laboratories $760 35 payments
  8. Amgen Inc. $678 38 payments
  9. AstraZeneca Pharmaceuticals LP $539 30 payments
  10. Janssen Pharmaceuticals, Inc $470 29 payments
  11. Other $3,035 122 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,593 426 payments
  2. Travel and Lodging $3,090 8 payments
  3. Education $409 5 payments
Products named General payments · program years 2019–2025
  1. Indigo System $2,915 9 payments
  2. Impella $1,295 11 payments
  3. ENTRESTO $1,063 64 payments
  4. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $739 11 payments
  5. Repatha $615 34 payments
  6. XARELTO $470 29 payments
  7. CT THROMBECTOMY SYSTEM KIT $434 4 payments
  8. FLOWTRIEVER CATHETER, S $434 4 payments
  9. BRILINTA $419 23 payments
  10. LifeVest $346 16 payments
  11. Other $5,271 245 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

6,068

Median for Interventional Cardiology: 2,236

Drug cost

$785,489

Median for Interventional Cardiology: $380,412

Branded share of claims

24.7%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 169 $180,126
Farxiga Dapagliflozin Propanediol Brand 118 $132,819
Entresto Sacubitril/Valsartan Brand 92 $118,075
Xarelto Rivaroxaban Brand 89 $110,608
Repatha Sureclick Evolocumab Brand 45 $46,331
Jardiance Empagliflozin Brand 37 $43,109
Brilinta Ticagrelor Brand 33 $35,762
Vascepa Icosapent Ethyl Brand 49 $34,079
Ranolazine Er Ranolazine Brand 68 $9,731
Rosuvastatin Calcium Generic 638 $8,991

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$69,167

Medicare's payments for the services billed

Medicare patients

360

Average age 74

Services billed

992

158 women, 202 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 73%
Arthritis 54%
Heart failure 50%
Diabetes 48%
Atrial fibrillation 44%
Chronic kidney disease 41%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $81
$81 37 —
VYNDAQEL
  • PFIZER INC. $53
$53 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $21
$21 — —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $18
$18 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $16
$16 89 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

439 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record